A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

NCT04825860 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

83

Enrollment

INDUSTRY

Sponsor class

Stopped Due to company business strategy

Conditions

Schizophrenia

Interventions

DRUG: SEP-363856 50 mg
DRUG: SEP-363856 75 mg
DRUG: Placebo

Sponsor

Sumitomo Pharma Co., Ltd.